B+
Bull case
25%
Probability
Target price
$31.00
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
HCSG
Healthcare Services GroupANasdaq / Commercial & Professional Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$27.00
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-26
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+70.5
Score
AI commentary
The initial reaction held through October 23: HCSG rose from $21.71 at the October 21 close to the packet's $25.30 October 23 anchor, about 16.5%. Historical prices News tone is positive on EPS and guidance, but the October 25 estimate aggregation found no material change in the $26.67 analyst target despite upward 2027 forecast revisions. Individual broker target or rating changes were not confirmed; social and options measures are unavailable. Simply Wall St
RankAlpha Sentiment Codex - 2026-10-26
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-30catalystPost-earnings estimate revisions versus unchanged targetMedium impact
A seven-analyst forecast aggregation raised 2027 revenue estimates from $2.06 billion to $2.16 billion and EPS from $1.19 to $1.22, while reporting no material change to its $26.67 price target. Further revisions may clarify whether the earnings improvement warrants another rerating. Simply Wall St, October 25
2026-12-31eventFourth-quarter revenue guidance testMedium impact
Following Q3 revenue of $479.6 million and EPS of $0.36, management guided Q4 revenue to $535–545 million. Delivery against that range is the clearest near-term test of the reported growth inflection. [#SEC-8K-2026-10-21] SEC earnings exhibit
2027-12-31catalystNEXDINE contribution and raised 2027 outlookHigh impact
HCSG completed its $93.5 million cash-funded NEXDINE acquisition and expects more than $150 million in annual revenue at comparable margins. It raised its 2027 revenue-growth outlook from mid-single digits to low double digits; integration and organic growth must substantiate that outlook. [#SEC-8K-2026-10-21] SEC earnings exhibit
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-26 • Updated nightlySource: Internal modelMethodology